



10340

Docket No.: C035795/0126287

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : )  
Seth LEDERMAN et al. )  
Serial No.: 09/930,864 )  
Filed: August 16, 2001 )

Examiner: Unassigned  
Art Unit: 1614

For: **ISOLATED FRAGMENTS OF p62  
NUCLEOPORIN AND USES THEREOF**

October 17, 2005

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

Sir:

This is in response to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES ("Notice") mailed September 13, 2005, which set a two-month shortened statutory period to respond. Accordingly, this response is filed timely upon mailing with an executed Certificate of Mailing on or before November 13, 2005. (37 C.F.R. § 1.8). It is not believed that this response occasions any fee, but should there be any fee, please charge the same to Deposit Account No. 02-4467. A duplicate copy of this sheet is enclosed.

BEST AVAILABLE COPY

## **REMARKS**

In the Notice, it is asserted that the Sequence Listing in computer readable form ("CRF") has not been submitted as required by 37 C.F.R. § 1.821(e). (See Notice at page 1). A copy of the Notice is attached hereto as Exhibit A.


In response to the Notice, a CRF copy of the Sequence Listing is attached hereto as Exhibit B. Although Applicants are submitting a CRF copy of the Sequence Listing as required by 37 C.F.R. § 1.821(e), Applicants would like to state for the record that a CRF copy of the Sequence Listing was previously submitted on April 21, 2003. See Exhibit C for a copy of the documents submitted on April 21, 2003 and the date stamped return postcard evidencing receipt by the Patent Office of the documents submitted on April 21, 2003. The date stamped post card is *prima facie* evidence that the documents were received by the Patent Office. See MPEP § 503.

Pursuant to 37 C.F.R. § 1.821(f), undersigned counsel hereby represents that, upon information and belief, the content of the paper copy filed concurrently with the patent application and the attached CRF of the Sequence Listing are the same, and no new matter has been added.


It is believed that the Sequence Listing presented herewith places the captioned application into compliance with the requirements set forth in 37 C.F.R. § 1.821. Entry of the Sequence Listing is respectfully solicited.


If the Examiner wishes to discuss any part of this submission, please  
contact the undersigned at the number indicated.

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as first  
class mail in an envelope addressed to: Mail Stop  
Missing Parts, Commissioner for Patents, P.O. Box  
1450, Alexandria, VA. 22313-1450, on October 17,  
2005.

  
Charles M. Avigliano, Reg. No. 52,578

Respectfully submitted,

By:   
Charles M. Avigliano  
Registration No. 52,578  
BRYAN CAVE LLP  
1290 Avenue of the Americas  
New York, NY 10104  
Phone: (212) 541-2000  
Fax: (212) 541-4630



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/930,864	08/16/2001	Seth Lederman	C35795/126287

Bryan Cave LLP  
 1290 Avenue of the Americas  
 33rd Floor  
 New York, NY 10104

CONFIRMATION NO. 3603

FORMALITIES  
 LETTER

Date Mailed: 09/13/2005

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

To Download Patentin Software, visit <http://www.uspto.gov/web/patents/software.htm>

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria VA 22313-1450

*A copy of this notice MUST be returned with the reply.*



Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382  
PART 2 - COPY TO BE RETURNED WITH RESPONSE

April 21, 2003

Docket No.: C35795/126287

In re Application of: S. LEDERMAN, et al.

Appl. No.: 09/930,864

Filed: August 16, 2001

For: ISOLATED FRAGMENTS OF p62 NUCLEOPORIN AND USES  
THEREOF

Enclosed:

1. Response to Notice to File Corrected Application Papers (2 pp., in dup.);
2. Exhibits A-C, which includes Statement & diskette of sequence listing;
3. Return postcard

PLEASE DATE STAMP AND RETURN  
TO ACKNOWLEDGE RECEIPT

CTW/tcr





Docket No.: C35795/126287

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of :

Seth LEDERMAN and Christopher GAMPER

Serial No.: 09/930,864

Filed: August 16, 2001

)  
)  
) Examiner: Unassigned

) Art Unit: 1614  
)  
)

For: **ISOLATED FRAGMENTS OF p62  
NUCLEOPORIN AND USES THEREOF**

April 21, 2003

**RESPONSE TO NOTICE TO FILE  
CORRECTED APPLICATION PAPERS**

Box Missing Parts  
Commissioner for Patents  
Washington, D.C. 20231

Sir:


In response to the February 21, 2003 "Notice to File Corrected Application Papers  
- Filing Date Granted" (copy enclosed as Exhibit A) in the above identified application,  
applicants are enclosing herewith the following:


- eight sheets (Figures 1-8) of replacement drawings in compliance with 37 C.F.R. 1.84 (Exhibit B);
- a Statement Under 37 C.F.R. 1.821(f) enclosing the "Sequence Listing" in computer readable form as required by 37 C.F.R. 1.821(e) (Exhibit C);

Accordingly, this response is filed timely upon mailing with an executed  
Certificate of Mailing on or before April 21, 2003. 35 U.S.C. §21(b); 37 CFR 1.8.

It is not believed that this response occasions any fee, but if any fee is required,  
the Commissioner is authorized to charge (or credit any overpayment) to Deposit Account No.  
02-4467.

Respectfully submitted,

By:   
Stephen J. Brown  
Reg. No. 43,519  
Bryan Cave LLP  
245 Park Avenue  
New York, NY 10167  
Phone: (212) 692-1800  
Fax: (212) 692-1900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, D.C. 20231, on April 21, 2003	
(Date of Deposit)	Stephen J. Brown
Name of applicant, assignee, or Registered Representative	
Signature	04/21/03
Date of Signature	





UNITED STATES  
PATENT AND  
TRADEMARK OFFICE



Commissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/930,864	08/16/2001	Seth Lederman	C35795/126287

Bryan Cave, LLP  
245 Park Avenue  
New York, NY 10167-0034

**CONFIRMATION NO. 3603**

**FORMALITIES LETTER**



\*OC000000009546117\*

Date Mailed: 02/21/2003

**NOTICE TO FILE CORRECTED APPLICATION PAPERS**

***Filing Date Granted***

An application number and filing date have been accorded to this application. The application is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given TWO MONTHS from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- Replacement drawings in compliance with 37 CFR 1.84 and 37 CFR 1.121 are required. The drawings submitted are not acceptable because:
  - The drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. ( 5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch). See Figures(s) 1, 2.
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

---

*A copy of this notice **MUST** be returned with the reply.*


*N<sup>n</sup>*

---


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



A



B





Figure 1

# A


## p62 Nucleoporin



AD/p62 fusion (aa)	TRAF-3 Interaction
63-522	+
170-522	+
185-522	+
187-522	+
200-522	+
219-522	+
270-522	+
336-522	+
63-302	-
301-393	-
301-474	+
335-409	-
336-438	+
360-409	-
360-438	+
360-474	+
410-437	-
410-474	-

# B

## TRAF-3



BD/TRAF-3 (aa)	Interaction TRAF-3 P62
1-568	+
1-107	-
1-265	-
46-107	-
46-343	+
46-568	+
110-265	-
110-343	+
110-568	+
229-294	ND
229-343	ND
267-343	+
288-343	-
288-568	+
419-568	-

Figure 2




Figure 3




Figure 4






Figure 5


A



B



C



D




Figure 6






Figure 7




Figure 8



Docket No.: C35795/126287

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : )  
Seth LEDERMAN and Christopher GAMPER ) Examiner: Unassigned  
Serial No.: 09/930,864 ) Art Unit: 1614  
Filed: August 16, 2001 )  
For: **ISOLATED FRAGMENTS OF p62**  
**NUCLEOPORIN AND USES THEREOF**

April 21, 2003

**STATEMENT UNDER 37 C.F.R. §1.821(f)**

Box Missing Parts  
Commissioner of Patents  
Washington, D.C. 20231


Sir:

I hereby state that the original Sequence Listing filed concurrently with patent application Serial No. 09/930,864 filed on August 16, 2001 for ISOLATED FRAGMENTS OF p62 NUCLEOPORIN AND USES THEREOF (copy enclosed as Exhibit 1), and the computer readable form submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United


States Code and that such willful false statements may jeopardize the validity of the application or any patent issue thereon.

Respectfully submitted,

By: 

Stephen J. Brown  
Reg. No. 43,519  
Bryan Cave LLP  
245 Park Avenue  
New York, NY 10167  
Phone: (212) 692-1800  
Fax: (212) 692-1900

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, D.C. 20231, on April 21, 2003	
(Date of Deposit)	
Stephen J. Brown	
Name of applicant, assignee, or Registered Representative	
	
Signature	
04/21/03	
Date of Signature	



# SEQUENCE LISTING

<110> LEDERMAN, et al. Dr., Seth

<120> ISOLATED FRAGMENTS OF p62 NUCLEOPORIN AND USES THEREOF

<130> Columbia University Sequence Listing

<140>

<141>

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 393

<212> PRT

<213> *Saccharomyces cerevisiae*

<400> 1

Met Ser Gly Phe Asn Phe Gly Gly Thr Gly Ala Pro Thr Gly Gly Phe  
1 5 10 15

Thr Phe Gly Thr Ala Lys Thr Ala Thr Thr Thr Pro Ala Thr Gly Phe  
20 25 30

Ser Phe Ser Thr Ser Gly Thr Gly Gly Phe Asn Phe Gly Ala Pro Phe  
35 40 45

Gln Pro Ala Thr Ser Thr Pro Ser Thr Gly Leu Phe Ser Leu Ala Thr  
50 55 60

Gln Thr Pro Ala Thr Gln Thr Thr Gly Phe Thr Phe Gly Thr Ala Thr  
65 70 75 80

Leu Ala Ser Gly Gly Thr Gly Phe Ser Leu Gly Ile Gly Ala Ser Lys  
85 90 95

Leu Asn Leu Ser Asn Thr Ala Ala Thr Pro Ala Met Ala Asn Pro Ser  
100 105 110

Gly Phe Gly Leu Gly Ser Ser Asn Leu Thr Asn Ala Ile Ser Ser Thr  
115 120 125

Val Thr Ser Ser Gln Gly Thr Ala Pro Thr Gly Phe Val Phe Gly Pro  
130 135 140

Ser Thr Thr Ser Val Ala Pro Ala Thr Thr Ser Gly Gly Phe Ser Phe  
 145 150 155 160  
 Thr Gly Gly Ser Thr Ala Gln Pro Ser Gly Phe Asn Ile Gly Ser Ala  
 165 170 175  
 Gly Asn Ser Ala Gln Pro Thr Ala Pro Ala Thr Leu Pro Phe Thr Pro  
 180 185 190  
 Ala Thr Pro Ala Ala Thr Thr Ala Gly Ala Thr Gln Pro Ala Ala Pro  
 195 200 205  
 Thr Pro Thr Ala Thr Ile Thr Ser Thr Gly Pro Ser Leu Phe Ala Ser  
 210 215 220  
 Ile Ala Thr Ala Pro Thr Ser Ser Ala Thr Thr Gly Leu Ser Leu Cys  
 225 230 235 240  
 Thr Pro Val Thr Thr Ala Gly Ala Pro Thr Ala Gly Thr Gln Gly Phe  
 245 250 255  
 Ser Leu Lys Ala Pro Gly Ala Ala Ser Gly Thr Ser Thr Thr Thr Ser  
 260 265 270  
 Thr Ala Ala Thr Ala Thr Ala Thr Thr Thr Thr Ser Ser Ser Thr Thr  
 275 280 285  
 Gly Phe Ala Leu Asn Leu Lys Pro Leu Ala Pro Ala Gly Ile Pro Ser  
 290 295 300  
 Asn Thr Ala Ala Ala Val Thr Ala Pro Pro Gly Pro Gly Ala Ala Ala  
 305 310 315 320  
 Gly Ala Ala Ala Ser Ser Ala Met Thr Tyr Ala Gln Leu Glu Ser Leu  
 325 330 335  
 Ile Asn Lys Trp Ser Leu Glu Leu Glu Asp Gln Glu Arg His Phe Leu  
 340 345 350  
 Gln Gln Ala Thr Gln Val Asn Ala Trp Asp Arg Thr Leu Ile Glu Asn  
 355 360 365  
 Gly Glu Lys Ile Thr Ser Leu His Arg Glu Val Glu Lys Val Lys Leu  
 370 375 380  
 Asp Gln Lys Arg Leu Asp Gln Glu Leu  
 385 390

<210> 2

<211> 187

<212> PRT

<213> *Saccharomyces cerevisiae*

<400> 2

Leu Ile Asn Lys Trp Ser Leu Glu Leu Glu Asp Gln Glu Arg His Phe  
1 5 10 15

Leu Gln Gln Ala Thr Gln Val Asn Ala Trp Asp Arg Thr Leu Ile Glu  
20 25 30

Asn Gly Glu Lys Ile Thr Ser Leu His Arg Glu Val Glu Lys Val Lys  
35 40 45

Leu Asp Gln Lys Arg Leu Asp Gln Glu Leu Asp Phe Ile Leu Ser Gln  
50 55 60

Gln Lys Glu Leu Glu Asp Leu Leu Ser Pro Leu Glu Glu Leu Val Lys  
65 70 75 80

Glu Gln Arg Ala Thr Ile Tyr Leu Gln His Ala Asp Glu Glu Arg Gln  
85 90 95

Lys Thr Tyr Lys Leu Ala Glu Asn Ile Asp Ala Gln Leu Lys Arg Met  
100 105 110

Ala Gln Asp Leu Lys Asp Ile Ile Glu His Leu Asn Thr Ser Gly Ala  
115 120 125

Pro Ala Asp Thr Ser Asp Pro Leu Gln Gln Ile Cys Lys Ile Leu Asn  
130 135 140

Ala His Met Asp Ser Leu Gln Trp Ile Asp Gln Asn Ser Ala Leu Leu  
145 150 155 160

Gln Arg Lys Val Glu Glu Val Thr Lys Val Cys Val Gly Arg Arg Lys  
165 170 175

Glu Gln Glu Arg Ser Phe Arg Ile Thr Phe Asp  
180 185



Format:	ASCII
Applicants:	Seth LEDERMAN, <i>et al.</i>
Serial No.:	09/930,864
Filed:	August 16, 2001
Title:	ISOLATED FRAGMENTS OF p62 NUCLEOPORIN AND USES THEREOF
Ref. No.:	C35795/126287
Date Recorded:	21-April-2003
Computer:	IBM PC Compatible
Operating Sys:	Windows 2000
Software:	Patentin Version 3.1
Medium:	3.5 inch diskette, high density 1.44 mb storage



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**